August 12, 2023
To | To |
Listing Department, | The Corporate Relations Department |
NATIONAL STOCK EXCHANGE OF INDIA LIMITED | BSE LIMITED |
Exchange Plaza, | Phiroz Jeejeebhoy Towers, |
Bandra Kurla Complex, Bandra (E), | 25th floor, Dalal Street, |
MUMBAI -400 051 | MUMBAI -400 001 |
Company Code No. AUROPHARMA | Company Code No. 524804 |
Dear Sir,
Sub: Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2023.
We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2023.
Please take the information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.08.12 18:20:03 +05'30'
B. Adi Reddy
Company Secretary
Encl.: As above
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: PlotNo. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel:+91 402373 6370/ 23747340 Fax: +914023741080/ 23746833 Email: info@aurobindo.com Website: www.aurobindo.com
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad - 500 032. Telangana, India
Investor Relations | Corporate Communications
Press ReleasePhone: 040-66725401 / 66725000
Email: ir@aurobindo.com
Hyderabad, India, August 12th, 2023: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended June 30, 2023.
Aurobindo Pharma Ltd. Q1FY24 Consolidated Financial Results
Amount (INR Cr)
Q1FY24
Q1FY23
% Change YoY
Q4FY23
- Change QoQ
Revenue from operations | 6,850.5 | 6,235.9 | 9.9% | 6,473.0 | 5.8% | ||||||||
EBITDA before Forex and Other Income | 1,151.4 | 964.7 | 19.3% | 1002.2 | 14.9% | ||||||||
EBITDA margin (%) | 16.8% | 15.5% | 134 bps | 15.5% | 132 bps | ||||||||
EBITDA before R&D | 1,539.0 | 1,274.8 | 20.7% | 1,412.9 | 8.9% | ||||||||
EBITDA margin before R&D (%) | 22.5% | 20.4% | 202 bps | 21.8% | 64 bps | ||||||||
PBT before share of P/L of JV, Forex, and Exceptional items | 846.9 | 711.2 | 19.1% | 713.3 | 18.7% | ||||||||
Net Profit after Share of Profit/Loss of JV and minority interest | 570.8 | 520.5 | 9.7% | 505.9 | 12.8% | ||||||||
Key highlights of Q1FY24
- Revenue from Operations at INR 6,850.5 Cr increased by 9.9% YoY
- US formulations revenue increased by 11.2% YoY to INR 3,304 Cr
- Europe formulation revenue stood at INR 1,837 Cr, with an increase of 18.6% YoY
- Growth Markets revenue grew by 12.9% YoY to INR 486 Cr
- ARV revenue stood at INR 190 Cr
- API revenue grew by 14.0% YoY to INR 1,033 Cr
- EBITDA before Forex and Other income stood at INR 1,151.4 Cr; EBITDA margin for the quarter was 16.8%.
- Research & Development (R&D) spend at INR 387.6 Cr, 5.7% of revenues (Q4 FY23: 6.3%)
- Received final approval for 19 ANDAs including 7 injectable products from the USFDA
- Net Profit after Share of Profit/Loss of JV and minority interest stood at INR 570.8 Cr, as against INR 520.5 Cr in Q1FY23
- Basic & Diluted EPS is INR 9.74 per share.
Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are pleased to start the new financial year on a good note with strong top-linegrowth and margin expansion aided by improved performance across our key markets. With our product pipeline continuing to advance, and execution of growth drivers proceeding as planned, we are confident that our fundamental strengths position us to create an upward trajectory. Looking ahead, we are confident in executing our growth initiatives and creating long-termvalue for our shareholders."
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad - 500 032. Telangana, India
Operational Performance (Consolidated)
Amount (INR Cr) | Q1FY24 | Q1FY23 | % Change YoY | Q4FY23 | % Change QoQ | ||||||||||||
Formulations | |||||||||||||||||
USA | 3,304 | 2,971 | 11.2% | 3,045 | 8.5% | ||||||||||||
Europe | 1,837 | 1,548 | 18.6% | 1,660 | 10.6% | ||||||||||||
Growth Markets* | 486 | 431 | 12.9% | 592 | -17.9% | ||||||||||||
ARV | 190 | 380 | -49.9% | 159 | 19.6% | ||||||||||||
Total Formulations | 5,817 | 5,329 | 9.2% | 5,456 | 6.6% | ||||||||||||
Active Pharmaceutical Ingredients (API) | |||||||||||||||||
Betalactam | 719 | 551 | 30.4% | 638 | 12.8% | ||||||||||||
Non Betalactam | 314 | 355 | -11.5% | 380 | -17.3% | ||||||||||||
Total API | 1,033 | 907 | 14.0% | 1,017 | 1.6% | ||||||||||||
Consolidated Gross Sales (incl. service | 6,851 | 6,236 | 9.9% | 6,473 | 5.8% | ||||||||||||
income) | |||||||||||||||||
Dossier Income | 0 | 0 | - | 0 | - | ||||||||||||
Revenue from operations | 6,851 | 6,236 | 9.9% | 6,473 | 5.8% | ||||||||||||
*includes domestic formulation sales of INR 52.4 Cr in Q1 FY24
Q1FY24: Consolidated revenue breakup - Geography & Segment wise
Q1FY24
Domestic, | |||||||||
11% | API, 15.1% | ||||||||
ARV, 2.8% | |||||||||
Growth | |||||||||
Markets, | |||||||||
7.1% | |||||||||
Europe, | |||||||||
International, | 26.8% | ||||||||
US, 48.2% | |||||||||
89% | |||||||||
Domestic | International | US | Europe | Growth Markets | ARV | API | |||
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad - 500 032. Telangana, India
Formulations
For the quarter, Formulation revenue increased by 9.2% YoY to INR 5,817 Cr
US Formulations
- In Q1 FY24, US revenue increased by 11.2% YoY to INR 3,304 Cr and accounted for 48.2% of consolidated revenues.
- Filed 12 ANDAs including 1 Injectable product with USFDA in Q1 FY24
- Received final approval for 19 ANDAs including 7 injectable products in Q1 FY24
- As on 30th June 2023, on a cumulative basis, the company has filed 814 ANDAs with USFDA and received 613 final approval and 34 tentative approval
- The company has launched 15 products during the quarter including 5 injectables.
Europe Formulations
- Europe revenue in Q1 FY24 increased by 18.6% YoY at INR 1,837 Cr. Europe Formulations accounted for 26.8% of consolidated revenue. In Euro terms, Europe revenue increased by 8.8% YoY to EUR 205.4 million.
ARV Formulations
- ARV business revenue for Q1 FY24 stood at INR 190 Cr, accounting for 2.8% of total revenue.
Growth Markets Formulations
- Revenue from Growth Markets formulations in Q1 FY24 posted a growth of 12.9% YoY to INR 486 Cr and accounted for 7.1% of revenue. Domestic formulation sales in Q1 FY24 was INR 52.4 Cr.
Active Pharmaceutical Ingredients (API)
- In Q1 FY24, API business stood at INR 1,033 Cr, increased by 14.0% YoY and contributed 15.1% to the consolidated revenue.
Global Regulatory Filings
Details
ANDAs (including filings from Aurobindo USA)
DMFs (including filings from Eugia and Auro Peptides)
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)
API filings in other key regulated markets (incl. multiple registrations)
Q1FY24 | Cumulative Filings as on | |||
30th June 2023 | ||||
12 | 814 | |||
- | 276 | |||
12 | 4,443 | |||
- | 3,730 | |||
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad - 500 032. Telangana, India
Final USFDA Approvals Received in Q1 FY24
# | Product | Therapy | |||||
1 | Apixaban Tablets, 2.5 mg and 5 mg | Cardiovascular | |||||
2 | Alcaftadine Ophthalmic Solution, 0.3% | Anti Histamine | |||||
3 | Macitentan Tablets, 10 mg | Cardiovascular | |||||
4 | Methylprednisolone Acetate Injectable Suspension USP, 400 mg/10 mL & 400 mg/5 mL | Anti Inflammatory | |||||
5 | Nitrofurantoin Oral Suspension USP, 25mg/5 mL | Anti Infective | |||||
6 | Omeprazole Delayed-Release Capsules (OTC), 20 mg | Gastrointestinal | |||||
7 | Roflumilast Tablets, 500 mcg | Anti Inflammatory | |||||
8 | Fexofenadine Hydrochloride Oral Suspension (OTC), 30 mg/5 mL | Anti Histamine | |||||
9 | Bendamustine Hydrochloride Injection, 100 mg/4 mL (25 mg/mL) [Multiple-Dose Vial] | Anti Neoplastic | |||||
10 | Estradiol and Norethindrone Acetate Tablets USP, 1 mg/0.5 mg and 0.5 mg/0.1 mg | Hormonal | |||||
11 | Cevimeline Hydrochloride Capsules, 30 mg | Prosecretory (Cholinergic Agonist) | |||||
12 | Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) [Single-Dose Prefilled Syringe] | Antiestrogen | |||||
13 | Phenoxybenzamine Hydrochloride Capsules USP, 10 mg | Cardiovascular | |||||
14 | Safinamide Tablets, 50 mg and 100 mg | Central Nervous System | |||||
15 | Tirofiban Hydrochloride Injection, 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50 | Antiplatelet | |||||
mcg/mL) [Single-Dose Flexible Container] | |||||||
16 | Carboprost Tromethamine Injection USP, 250 mcg/mL [Single-Dose Vial] | Oxytocic Agent | |||||
17 | Rufinamide Tablets USP, 200 mg and 400 mg | Central Nervous System | |||||
18 | Tobramycin for Injection USP, 1.2 g/Vial [Pharmacy Bulk Package] | Aminoglycoside Antibacterial | |||||
19 | Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial | Anti Fungal | |||||
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Aurobindo Pharma Ltd. published this content on 12 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 August 2023 08:24:06 UTC.